Osteosarcoma
The commonest bone cancer in teenagers; relapsed and metastatic disease remain hard to treat.
Principal investigators and study chairs named on the registry for osteosarcoma, ranked by a published score: 3 per Phase 2+ trial they lead, 1 per other trial role, 2 per oral or late-breaking talk and 0.5 per poster in our verified 2026 meeting rows, each halved every 24 months. Paper authorship is not scored yet. PubMed counts are author name plus indication, for the top 12; names are as the registry spells them, so a common name can pool several people. Open a row for their trials and links to their papers.
Jonathan MettsMoffitt Cancer Centerscore 3.4
Score 3.4 = 2.7 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.
Joseph LudwigM.D. Anderson Cancer Centerscore 3
Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Juan C VasquezPediatric Early Phase Clinical Trial Networkscore 3
Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Lung-Ji ChangShenzhen Geno-Immune Medical Institutescore 3
Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Thomas RussellAlliance for Research and Innovations in Pediatric Oncology (ARISE) Cancer Consortiumscore 3
Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Natacha ENTZ WERLEHopitaux Universitaires de Strasbourgscore 2.9
Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Silvia StacchiottiS.C. Oncologia Medica 2, Tumori Mesenchimali e Rari, Fondazione IRCCS, Istituto Nazionale dei Tumoriscore 2.9
Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Julie ParkSt. Jude Children's Research Hospitalscore 2.8
Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Amy ArmstrongWashington University School of Medicinescore 2.7
Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Giselle SaulnierShollerPenn State Health Children's Hospitalscore 2.6
Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Giselle Saulnier ShollerPenn State Health Children's Hospitalscore 2.5
Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
John LivingstonM.D. Anderson Cancer Centerscore 2.5
Score 2.5 = 2.2 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.
- Ph2NCT07193550 · M.D. Anderson Cancer Center · A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
- Ph1NCT05621668 · M.D. Anderson Cancer Center · A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
Damon ReedMemorial Sloan Kettering Cancer Centerscore 2.4–
Score 2.4 = 2.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Jordan MilnerUniversity of Floridascore 2.3–
Score 2.3 = 2.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Bhuvana A SettyChildren's Oncology Groupscore 2.1–
Score 2.1 = 2.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Matteo TruccoCleveland Clinic Hospitalscore 2–
Score 2 = 0 leading Phase 2+ trials + 2 other trial roles + 0 talks + 0 posters. 0 of 3 trials are Phase 2+.
- Ph1NCT07194044 · H. Lee Moffitt Cancer Center and Research Institute · Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
- Ph1NCT07695311 · Rabi Hanna · EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT
- Ph1NCT05210374 · Case Comprehensive Cancer Center · Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Alice LeeChildren's Oncology Groupscore 1.9–
Score 1.9 = 1.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.
- Ph2NCT03210714 · National Cancer Institute (NCI) · Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
- Ph1/Ph2NCT06892678 · Montefiore Medical Center · DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
Thomas CashEmory Universityscore 1.8–
Score 1.8 = 0.1 leading Phase 2+ trials + 1.7 other trial roles + 0 talks + 0 posters. 1 of 3 trials are Phase 2+.
- Ph1NCT07144254 · Emory University · Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
- Ph1NCT06492954 · Emory University · Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
- Ph2NCT02574728 · Emory University · Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
John LigonUniversity of Floridascore 1.7–
Score 1.7 = 1.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
David ShulmanDana-Farber Cancer Institutescore 1.6–
Score 1.6 = 1.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Chandrika BehuraPenn State Health Children's Hospitalscore 1.5–
Score 1.5 = 1.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Christine M HeskeNational Cancer Institute (NCI)score 1.5–
Score 1.5 = 1.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Hong-Tao LiShanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospitalscore 1.5–
Score 1.5 = 1.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Pedro Hermida de ViveirosNorthwestern Universityscore 1.4–
Score 1.4 = 1.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Camila MV MonizOncologistscore 1.3–
Score 1.3 = 1.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Karen MoodyMD Andersonscore 1.3–
Score 1.3 = 1.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Katharine OfferHackensack Meridian Healthscore 1.3–
Score 1.3 = 1.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Sarah HalesUniversity Health Network, Torontoscore 1.3–
Score 1.3 = 1.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Theodore LaetschChildren's Hospital of Philadelphiascore 1.3–
Score 1.3 = 1 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.
Jessica GartrellSt. Jude Children's Research Hospitalscore 1.2–
Score 1.2 = 1.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Yang YaoShanghai 6th People's Hospitalscore 1.2–
Score 1.2 = 1.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
John A LivingstonM.D. Anderson Cancer Centerscore 1.1–
Score 1.1 = 1.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.
- Ph1/Ph2NCT03598595 · M.D. Anderson Cancer Center · Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
- Ph2NCT05019703 · M.D. Anderson Cancer Center · Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
Neeta SomaiahM.D. Anderson Cancer Centerscore 1.1–
Score 1.1 = 0.4 leading Phase 2+ trials + 0.7 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.
- Ph2NCT04668300 · M.D. Anderson Cancer Center · Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
- Ph1NCT06474676 · M.D. Anderson Cancer Center · T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
Fiorella Iglesias CardenasMemorial Sloan Kettering Kidsscore 1–
Score 1 = 1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Martin EbingerUniversity children's hospital Tübingenscore 1–
Score 1 = 1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Claudia RossigUniversity Children´s Hospital Münsterscore 1–
Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.
Peter M AndersonCase Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institutescore 1–
Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.
Timothy A ChanCase Comprehensive Cancer Center, Cleveland Clinic Center for Immunotherapy and Immuno-Oncologyscore 1–
Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.
David HongM.D. Anderson Cancer Centerscore 0.9–
Score 0.9 = 0.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.
Leander D TimothyBaylor College of Medicinescore 0.9–
Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.